ArticleCureus2025
A Single-Center Prospective Study on Adverse Drug Reactions Associated With Polypharmacy in Elderly Outpatients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolypharmacy in elderly patients significantly increases the risk of adverse drug reactions (ADRs), posing a challenge to safe outpatient care.
objectiveTo prospectively evaluate the frequency, nature, and clinical outcomes of ADRs associated with polypharmacy in elderly outpatients. METHODOLOGY: A prospective observational study was conducted at the outpatient department of Azad Jammu and Kashmir Medical College (AJKMC), Muzaffarabad, over one year from June 2023 to May 2024. Through convenience sampling, 246 individuals who were at least 60 years old and using five or more drugs were included. Medical record reviews and structured patient interviews were used to gather data. The FDA Toxicity Grading Scale was used to classify ADRs according to their severity after they were evaluated using the FDA Toxicity Grading Scale. SPSS version 25.0 (IBM Corp., Armonk, NY) was used for the statistical analysis, and
resultsOf the 246 patients, 132 patients (53.66%) were male and 114 patients (46.34%) were female. The most common comorbidities were hypertension in 151 patients (61.38%), type 2 diabetes mellitus in 103 patients (41.87%), and ischemic heart disease in 89 patients (36.18%). Regarding polypharmacy, 94 patients (38.21%) were taking 5-6 medications, 87 patients (35.37%) were on 7-8 medications, and 65 patients (26.42%) were on 9 or more medications. A total of 76 patients (30.89%) experienced at least one ADR. The most frequently affected systems were gastrointestinal in 28 patients (11.38%) and dermatological in 17 patients (6.91%). ADRs were significantly more common in patients aged ≥80 years (16 out of 41, 39.02%), in those taking ≥9 medications (30 out of 65, 46.15%), and in those with two or more comorbidities (52 out of 121, 43.70%) (
conclusionsPolypharmacy in elderly outpatients is strongly associated with clinically significant ADRs, warranting routine medication review and vigilant pharmacovigilance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.